rts logo

Positives for Iovance Biotherapeutics Inc (IOVA) as stock gains in recent trading

Iovance Biotherapeutics Inc (NASDAQ: IOVA) is 69.37% higher on its value in year-to-date trading and has touched a low of $3.21 and a high of $18.33 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The IOVA stock was last observed hovering at around $14.19 in the last trading session, with the day’s loss setting it -0.42%.

Currently trading at $13.77, the stock is -8.36% and 11.00% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 5.51 million and changing -2.96% at the moment leaves the stock 76.56% off its SMA200. IOVA registered 123.90% gain for a year compared to 6-month gain of 202.64%. The firm has a 50-day simple moving average (SMA 50) of $3.06k and a 200-day simple moving average (SMA200) of -$8.51.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The stock witnessed a -17.99% loss in the last 1 month and extending the period to 3 months gives it a 69.37%, and is -5.23% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.93% over the week and 6.73% over the month.

Iovance Biotherapeutics Inc (IOVA) has around 557 employees, a market worth around $3.85B and $1.19M in sales. Profit margin for the company is -37345.42%. Distance from 52-week low is 328.97% and -24.88% from its 52-week high. The company has generated returns on investments over the last 12 months (-68.03%).

Iovance Biotherapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.42 with sales reaching $2.07M over the same period.The EPS is expected to grow by 30.65% this year, but quarterly earnings will post 13,547.60% year-over-year. Quarterly sales are estimated to grow 935.00% in year-over-year returns.

Iovance Biotherapeutics Inc (IOVA) Top Institutional Holders

338 institutions hold shares in Iovance Biotherapeutics Inc (IOVA), with institutional investors hold 89.70% of the company’s shares. The shares outstanding are 256.14M, and float is at 219.99M with Short Float at 21.56%. Institutions hold 89.20% of the Float.

The top institutional shareholder in the company is Vanguard Group Inc with over 20.4 million shares valued at $143.58 million. The investor’s holdings represent 8.23% of the IOVA Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 17.0 million shares valued at $119.69 million to account for 6.86% of the shares outstanding. The other top investors are Perceptive Advisors Llc which holds 14.04 million shares representing 5.66% and valued at over $98.82 million, while State Street Corporation holds 5.48% of the shares totaling 13.57 million with a market value of $95.5 million.

Iovance Biotherapeutics Inc (IOVA) Insider Activity

The most recent transaction is an insider purchase by Rothbaum Wayne P.,the company’sDirector. SEC filings show that Rothbaum Wayne P. bought 5,000,000 shares of the company’s common stock on Feb 20 ’24 at a price of $9.15 per share for a total of $45.75 million. Following the purchase, the insider now owns 28.07 million shares.

Iovance Biotherapeutics Inc disclosed in a document filed with the SEC on Feb 20 ’24 that MCPEAK MERRILL A (Director) bought a total of 250,000 shares of the company’s common stock. The trade occurred on Feb 20 ’24 and was made at $9.15 per share for $2.29 million. Following the transaction, the insider now directly holds 0.32 million shares of the IOVA stock.

Still, SEC filings show that on Feb 20 ’24, Dukes Iain D. (Director) acquired 32,000 shares at an average price of $9.15 for $0.29 million. The insider now directly holds 54,000 shares of Iovance Biotherapeutics Inc (IOVA).

Related Posts